RPL7P39

Across TCGA pan-cancer cohorts, RPL7P39 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RPL7P39’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL7P39 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL7P39 is over-expressed in tumor, although a few such as LUSC and THCA show the opposite, repressed pattern.

BRCA, COAD, and STAD are the cancer types where RPL7P39 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL7P39 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	+0.124	.002	4	view →
COAD	All	All	+0.107	.006	4	view →
STAD	All	II,III,IV	+0.083	.024	4	view →
LUSC	All	All	−0.078	.022	4	view →
PRAD	All	All	+0.108	.004	2	view →
THCA	All	II,III,IV	−0.041	.033	2	view →
ESCA	All	All	+0.295	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RPL7P39–BRCA

Open the BRCA breakdown →